Lakefront Biotherapeutics (GLPGF) EPS (Basic) Growth (1y) (2015 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EPS (Basic) Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.55 Bn | 197.56 Bn | 7.24 Bn | 65.24% |
| 2 | Gilead Sciences | 181.17 Bn | 177.99 Bn | 6.22 Bn | -636.10% |
| 3 | Vertex Pharmaceuticals | 132.18 Bn | 124.33 Bn | 2.84 Bn | 7.74% |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | -4.72% |
| 5 | Argenx Se | 61.66 Bn | 56.48 Bn | 1.37 Bn | 87.85% |
| 6 | Moderna | 54.61 Bn | 49.47 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 34.17 Bn | 30.86 Bn | 992.69 Mn | 322.67% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -84.77% |
| 9 | Roivant Sciences | 30.04 Bn | 30.04 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -128.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -128.49% |
| Mar 31, 2026 | 110.51% |
| Dec 31, 2025 | 372.83% |
| Sep 30, 2025 | -447.30% |
| Jun 30, 2025 | 207.44% |
| Mar 31, 2025 | -264.60% |
| Dec 31, 2024 | -65.27% |
| Sep 30, 2024 | -200.60% |
| Jun 30, 2024 | 8,928.96% |
| Mar 31, 2024 | 292.37% |
| Dec 31, 2023 | 97,187.36% |
| Sep 30, 2023 | -261.99% |
| Jun 30, 2023 | 103.11% |
| Mar 31, 2023 | 266.24% |
| Dec 31, 2022 | 470.06% |
| Sep 30, 2022 | 111.90% |
| Jun 30, 2022 | 73.96% |
| Mar 31, 2022 | -226.49% |
| Dec 31, 2021 | 70.84% |
| Sep 30, 2021 | 15.56% |